His win rate puts Warren Buffett to shame…

Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.

Mark Enyedy Biography and Net Worth

CEO of ImmunoGen

Mark J. Enyedy J.D. serves as President, Chief Executive Officer, Director of the Company. Prior to joining ImmunoGen, he served in various executive capacities at Shire PLC, a pharmaceutical company, from 2013 to 2016, including as Executive Vice President and Head of Corporate Development from 2014 to 2016, where he led Shire’s strategy, M&A and corporate planning functions and provided commercial oversight of Shire’s pre-Phase 3 portfolio. Prior to joining Shire, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from 2011 to 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Mr. Enyedy holds a JD from Harvard Law School and practiced law prior to joining Genzyme. Mr. Enyedy is also a director of Akebia Therapeutics, LogicBio Therapeutics, Inc., and The American Cancer Society of Eastern New England. Within the past five years, he also served as a director of Fate Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.

What is Mark J. Enyedy's net worth?: The estimated net worth of Mark J. Enyedy is at least $13.79 million as of August 3rd, 2023. Mr. Enyedy owns 441,449 shares of ImmunoGen stock worth more than $13,786,452 as of April 28th. This net worth evaluation does not reflect any other investments that Mr. Enyedy may own. Additionally, Mr. Enyedy receives a salary of $1,280,000.00 as CEO at ImmunoGen. Learn More about Mark J. Enyedy's net worth.
How old is Mark J. Enyedy?: Mr. Enyedy is currently 60 years old. There are 4 older executives and no younger executives at ImmunoGen. Learn More on Mark J. Enyedy's age.
What is Mark J. Enyedy's salary?: As the CEO of ImmunoGen, Inc., Mr. Enyedy earns $1,280,000.00 per year. Learn More on Mark J. Enyedy's salary.
How do I contact Mark J. Enyedy?: The corporate mailing address for Mr. Enyedy and other ImmunoGen executives is 830 WINTER ST, WALTHAM MA, 02451. ImmunoGen can also be reached via phone at (781) 895-0600 and via email at [email protected]. Learn More on Mark J. Enyedy's contact information.
Has Mark J. Enyedy been buying or selling shares of ImmunoGen?: Mark J. Enyedy has not been actively trading shares of ImmunoGen over the course of the past ninety days. Most recently, Mark J. Enyedy sold 1,020,000 shares of the business's stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $16.61, for a transaction totalling $16,942,200.00. Following the completion of the sale, the chief executive officer now directly owns 441,449 shares of the company's stock, valued at $7,332,467.89. Learn More on Mark J. Enyedy's trading history.
Who are ImmunoGen's active insiders?: ImmunoGen's insider roster includes Susan Altschuller (Sr. VP & CFO ), Stacy Coen (SVP), Mark Enyedy (Pres), Mark Enyedy (CEO), Renee Lentini (Insider), Kristine Peterson (Director), and Theresa Wingrove (SVP). Learn More on ImmunoGen's active insiders.
Are insiders buying or selling shares of ImmunoGen?: During the last year, insiders at the biotechnology company sold shares 16 times. They sold a total of 2,559,547 shares worth more than $45,624,932.36. The most recent insider tranaction occured on January, 16th when SVP Theresa Wingrove sold 187,667 shares worth more than $5,562,449.88. Insiders at ImmunoGen own 5.1% of the company. Learn More about insider trades at ImmunoGen.
Information on this page was last updated on 1/16/2024.

Mark J. Enyedy Insider Trading History at ImmunoGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/3/2023	Sell	1,020,000	$16.61	$16,942,200.00	441,449
2/24/2020	Sell	55,222	$4.99	$275,557.78	433,776
2/22/2019	Sell	51,070	$5.60	$285,992.00	483,768
2/21/2018	Sell	67,717	$10.87	$736,083.79	532,383
11/8/2016	Buy	25,000	$1.83	$45,750.00	100,100

Mark J. Enyedy Buying and Selling Activity at ImmunoGen

ImmunoGen Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Today's Range

Now: $31.23

$31.23

50 Day Range

MA: $31.23

$31.23

2 Week Range

Now: $31.23

$3.61

$31.25

Volume

40 shs

Average Volume

8,778,325 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

His win rate puts Warren Buffett to shame…

From Investing Daily | Ad

Click here now for the full story.

Mark Enyedy Biography and Net Worth

What is Mark J. Enyedy's net worth?

How old is Mark J. Enyedy?

What is Mark J. Enyedy's salary?

How do I contact Mark J. Enyedy?

Has Mark J. Enyedy been buying or selling shares of ImmunoGen?

Who are ImmunoGen's active insiders?

Are insiders buying or selling shares of ImmunoGen?